TPWA
CSTL icon

Twin Peaks Wealth Advisors’s Castle Biosciences CSTL Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25 Buy
+1
New +$33 ﹤0.01% 2336
2025
Q3 		– Sell
-1
Closed -$19 – 599
2025
Q2 		$19 Buy
+1
New +$19 ﹤0.01% 2252

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Twin Peaks Wealth Advisors's CSTL Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in Castle Biosciences (CSTL) in Q1 2026: 1 share worth $25. The stake represents ﹤0.01% of the portfolio and ranks #2336 among its holdings. This is a return to the name: Twin Peaks Wealth Advisors previously reported a position in CSTL as recently as Q2 2025.

Twin Peaks Wealth Advisors first reported a position in CSTL in Q2 2025 and has held it in 2 quarters since. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Twin Peaks Wealth Advisors held 1 share of Castle Biosciences worth $25 as of Q1 2026.
  • Castle Biosciences was a new Twin Peaks Wealth Advisors position in Q1 2026.
  • Castle Biosciences made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #2336 holding.
  • Twin Peaks Wealth Advisors first reported a position in Castle Biosciences in Q2 2025 and has held it in 2 quarters since.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.